scientific expert at the bench in the assay service lab
graphic stem cell

Assay Service

Current drug development strategies can be costly and too often experience high failure rates in later stages of development. Accordingly, cell-based assays are important tools to screen new drug candidates before moving to expensive animal models testing. Our seasoned assay experts are dedicated to accelerating your screening capabilities. Save valuable time for your research with our assay service by outsourcing time-consuming workflows to us.

Main Advantages of trenzyme’s Assay Service

Pharmaceutical companies utilize a variety of ways for drug discovery. In the past, a large number of compounds have been tested in high-throughput biochemical assays. However, the complexity of disease backgrounds raised the need for more physiological systems, increasing the use of cell-based assays to predict the response of the organism. trenzyme is specialized in cell-based assays using various cell lines and up-to-date technologies. Our highly skilled experts are capable of developing custom cell-based assays and producing reliable results to help you accelerate your screening capabilities. Furthermore, together with our stem cell experts, complex predictive and translational in vitro assays can be combined to highly physiological human stem cell-derived cell types, enabling advanced compound testing solutions.


  • Benefit from a full technology transfer of your assay or let our assay service develop your assays according to your needs
  • Development of assays based on basic cell lines, customized cell lines or iPSC-derived cell types
  • Broad expertise in assay development for in-vitro-toxicology and pharmaceutical testing
  • Wide range of techniques to measure endpoints (FACS, Immunostaining, ELISA, Western blot, qPCR)
  • Custom cell line service enables the production of assay cell lines
  • GMP-like documentation available on request

“We particularly appreciate the fast and excellent communication, the high flexibility of trenzyme’s team and the outstanding project management, which brought our project to a successful outcome. Thanks to the whole team of professional scientific experts for all the valuable advices!”

Dr. Katrin Berger

breeding botanicals international AG, Uttwil, Switzerland

Process of Assay Service

diagram of the process of trenzyme‘s assay service
Your benefits from working with us
Transparency & Communication
Your  project manager keeps you constantly informed on the progress of your project.
Longstanding Expertise
Since 2000, our highly qualified scientific experts accelerate your innovation.
Optimized Process
trenzyme‘s assay service enable a time-saving workflow for your project.
High Quality Standards
As an ISO-certified company, all projects are completed following high standards.

Assay Services

Assay Services using a standard cell line: HepG2

Relevant Publications

Classification of Developmental Toxicants in a Human iPSC Transcriptomics-Based Test. Chemical Research in Toxicology 2022 35 (5), 760-773 (2022)

Cherianidou A, Seidel F, Kappenberg F, Dreser N, Blum J, Waldmann T, Blüthgen N, Meisig J, Madjar K, Henry M, Rotshteyn T, Marchan R, Edlund K, Leist M, Rahnenführer J, Sachinidis A, and Hengstler JG

Read more

A human stem cell-derived test system for agents modifying neuronal N-methyl-D-aspartate-type glutamate receptor Ca2+-signalling. Arch Toxicol. 2021 May;95(5):1703-1722. (2021)

Klima S, Brüll M, Spreng AS, Suciu I, Falt T, Schwamborn JC, Waldmann T, Karreman C, Leist M

Read more

Development of a neural rosette formation assay (RoFA) to identify neurodevelopmental toxicants and to characterize their transcriptome disturbances. Arch Toxicol. 2020 Jan;94(1):151-171. doi: 10.1007/s00204-019-02612-5. Epub 2019 Nov 11. PMID: 31712839. (2020)

Dreser N, Madjar K, Holzer AK, Kapitza M, Scholz C, Kranaster P, Gutbier S, Klima S, Kolb D, Dietz C, Trefzer T, Meisig J, van Thriel C, Henry M, Berthold MR, Blüthgen N, Sachinidis A, Rahnenführer J, Hengstler JG, Waldmann T, and Leist M

Read more

Establishment of a human iPS cell-derived neuronal model cell to study synaptic signaling (2020)

Traub S

Read more

The EU-ToxRisk method documentation, data processing and chemical testing pipeline for the regulatory use of new approach methods. Arch Toxicol. 2020 Jul;94(7):2435-2461. doi: 10.1007/s00204-020-02802-6. Epub 2020 Jul 6. PMID: 32632539; PMCID: PMC7367925. (2020)

Krebs A, van Vugt-Lussenburg BMA, Waldmann T, Albrecht W, Boei J, Ter Braak B, Brajnik M, Braunbeck T, Brecklinghaus T, Busquet F, Dinnyes A, Dokler J, Dolde X, Exner TE, Fisher C, Fluri D, Forsby A, Hengstler JG, Holzer AK, Janstova Z, Jennings P, Kisitu J, Kobolak J, Kumar M, Limonciel A, Lundqvist J, Mihalik B, Moritz W, Pallocca G, Ulloa APC, Pastor M, Rovida C, Sarkans U, Schimming JP, Schmidt BZ, Stöber R, Strassfeld T, van de Water B, Wilmes A, van der Burg B, Verfaillie CM, von Hellfeld R, Vrieling H, Vrijenhoek NG, and Leist M

Read more

Examination of microcystin neurotoxicity using central and peripheral human neurons. ALTEX. 2021;38(1):73-81. doi: 10.14573/altex.2003182. Epub 2020 Jun 23. PMID: 32591837. (2020)

Klima S, Suciu I, Hoelting L, Gutbier S, Waldmann T, Dietrich DR, and Leist M

Read more

Template for the description of cell-based toxicological test methods to allow evaluation and regulatory use of the data. ALTEX. 2019;36(4):682-699. doi: 10.14573/altex.1909271. Erratum in: ALTEX. 2020;37(1):164. PMID: 31658359. (2019)

Krebs A, Waldmann T, Wilks MF, Van Vugt-Lussenburg BMA, Van der Burg B, Terron A, Steger-Hartmann T, Ruegg J, Rovida C, Pedersen E, Pallocca G, Luijten M, Leite SB, Kustermann S, Kamp H, Hoeng J, Hewitt P, Herzler M, Hengstler JG, Heinonen T, Hartung T, Hardy B, Gantner F, Fritsche E, Fant K, Ezendam J, Exner T, Dunkern T, Dietrich DR, Coecke S, Busquet F, Braeuning A, Bondarenko O, Bennekou SH, Beilmann M, and Leist M

Read more

Major changes of cell function and toxicant sensitivity in cultured cells undergoing mild, quasi-natural genetic drift. Arch Toxicol. 2018 Dec;92(12):3487-3503. doi: 10.1007/s00204-018-2326-5. Epub 2018 Oct 8. Erratum in: Arch Toxicol. 2019 Jun;93(6):1771. PMID: 30298209; PMCID: PMC6290691. (2018)

Gutbier S, May P, Berthelot S, Krishna A, Trefzer T, Behbehani M, Efremova L, Delp J, Gstraunthaler G, Waldmann T, Leist M

Read more

Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity. ALTEX. 2018;35(3):306-352. doi: 10.14573/altex.1712081. Epub 2018 Feb 23. Erratum in: ALTEX. 2019;36(3):506. PMID: 29485663; PMCID: PMC6545888. (2018)

Bal-Price A, Hogberg HT, Crofton KM, Daneshian M, FitzGerald RE, Fritsche E, Heinonen T, Hougaard Bennekou S, Klima S, Piersma AH, Sachana M, Shafer TJ, Terron A, Monnet-Tschudi F, Viviani B, Waldmann T, Westerink RHS, Wilks MF, Witters H, Zurich MG, and Leist M

Read more

Stage-specific metabolic features of differentiating neurons: Implications for toxicant sensitivity. Toxicol Appl Pharmacol. 2018 Sep 1;354:64-80. doi: 10.1016/j.taap.2017.12.013. Epub 2017 Dec 24. Erratum in: Toxicol Appl Pharmacol. 2019 Jun 1;372:70. PMID: 29278688. (2018)

Delp J, Gutbier S, Cerff M, Zasada C, Niedenführ S, Zhao L, Smirnova L, Hartung T, Borlinghaus H, Schreiber F, Bergemann J, Gätgens J, Beyss M, Azzouzi S, Waldmann T, Kempa S, Nöh K, and Leist M

Read more

Adverse outcome pathways: opportunities, limitations and open questions. Arch Toxicol. 2017 Nov;91(11):3477-3505. doi: 10.1007/s00204-017-2045-3. Epub 2017 Oct 19. PMID: 29051992. (2017)

Leist M, Ghallab A, Graepel R, Marchan R, Hassan R, Bennekou SH, Limonciel A, Vinken M, Schildknecht S, Waldmann T, Danen E, van Ravenzwaay B, Kamp H, Gardner I, Godoy P, Bois FY, Braeuning A, Reif R, Oesch F, Drasdo D, Höhme S, Schwarz M, Hartung T, Braunbeck T, Beltman J, Vrieling H, Sanz F, Forsby A, Gadaleta D, Fisher C, Kelm J, Fluri D, Ecker G, Zdrazil B, Terron A, Jennings P, van der Burg B, Dooley S, Meijer AH, Willighagen E, Martens M, Evelo C, Mombelli E, Taboureau O, Mantovani A, Hardy B, Koch B, Escher S, van Thriel C, Cadenas C, Kroese D, van de Water B, and Hengstler JG

Read more

Combination of multiple neural crest migration assays to identify environmental toxicants from a proof-of-concept chemical library. Arch Toxicol. 2017 Nov;91(11):3613-3632. doi: 10.1007/s00204-017-1977-y. Epub 2017 May 5. PMID: 28477266. (2017)

Nyffeler J, Dolde X, Krebs A, Pinto-Gil K, Pastor M, Behl M, Waldmann T, and Leist M

Read more

Stem Cell-Derived Immature Human Dorsal Root Ganglia Neurons to Identify Peripheral Neurotoxicants. Stem Cells Transl Med. 2016 Apr;5(4):476-87. doi: 10.5966/sctm.2015-0108. Epub 2016 Mar 1. PMID: 26933043; PMCID: PMC4798731. (2016)

Hoelting L, Klima S, Karreman C, Grinberg M, Meisig J, Henry M, Rotshteyn T, Rahnenführer J, Blüthgen N, Sachinidis A, Waldmann T, and Leist M

Read more

Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80. doi: 10.1007/s00204-015-1658-7. Epub 2015 Dec 26. PMID: 26705709; PMCID: PMC4710658. (2016)

Pallocca G, Grinberg M, Henry M, Frickey T, Hengstler JG, Waldmann T, Sachinidis A, Rahnenführer J, and Leist M

Read more

A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis. Arch Toxicol. 2016 Nov;90(11):2725-2743. doi: 10.1007/s00204-015-1637-z. Epub 2015 Dec 8. PMID: 26647301; PMCID: PMC5065586. (2016)

Smirnova L, Harris G, Delp J, Valadares M, Pamies D, Hogberg HT, Waldmann T, Leist M, and Hartung T

Read more

A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618. doi: 10.1007/s00204-015-1573-y. Epub 2015 Aug 14. PMID: 26272509; PMCID: PMC4551554. (2015)

Rempel E, Hoelting L, Waldmann T, Balmer NV, Schildknecht S, Grinberg M, Das Gaspar JA, Shinde V, Stöber R, Marchan R, van Thriel C, Liebing J, Meisig J, Blüthgen N, Sachinidis A, Rahnenführer J, Hengstler JG, and Leist M

Read more

Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling. Neurotoxicology. 2015 Sep;50:56-70. doi: 10.1016/j.neuro.2015.07.008. Epub 2015 Jul 31. PMID: 26238599. (2015)

Dreser N, Zimmer B, Dietz C, Sügis E, Pallocca G, Nyffeler J, Meisig J, Blüthgen N, Berthold MR, Waldmann T, and Leist M

Read more

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation. J Vis Exp. 2015 Jun 17;(100):e52333. doi: 10.3791/52333. PMID: 26132533; PMCID: PMC4544843. (2015)

Shinde V, Klima S, Sureshkumar PS, Meganathan K, Jagtap S, Rempel E, Rahnenführer J, Hengstler JG, Waldmann T, Hescheler J, Leist M, and Sachinidis A

Read more

Toxicogenomics directory of chemically exposed human hepatocytes. Arch Toxicol. 2014 Dec;88(12):2261-87. doi: 10.1007/s00204-014-1400-x. Epub 2014 Nov 16. PMID: 25399406. (2014)

Grinberg M, Stöber RM, Edlund K, Rempel E, Godoy P, Reif R, Widera A, Madjar K, Schmidt-Heck W, Marchan R, Sachinidis A, Spitkovsky D, Hescheler J, Carmo H, Arbo MD, van de Water B, Wink S, Vinken M, Rogiers V, Escher S, Hardy B, Mitic D, Myatt G, Waldmann T, Mardinoglu A, Damm G, Seehofer D, Nüssler A, Weiss TS, Oberemm A, Lampen A, Schaap MM, Luijten M, van Steeg H, Thasler WE, Kleinjans JC, Stierum RH, Leist M, Rahnenführer J, and Hengstler JG

Read more

From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68. doi: 10.1007/s00204-014-1279-6. Epub 2014 Jun 17. PMID: 24935251; PMCID: PMC4067541. (2014)

Balmer NV, Klima S, Rempel E, Ivanova VN, Kolde R, Weng MK, Meganathan K, Henry M, Sachinidis A, Berthold MR, Hengstler JG, Rahnenführer J, Waldmann T, and Leist M

Read more

Profiling of drugs and environmental chemicals for functional impairment of neural crest migration in a novel stem cell-based test battery. Arch Toxicol. 2014 May;88(5):1109-26. doi: 10.1007/s00204-014-1231-9. Epub 2014 Apr 2. PMID: 24691702; PMCID: PMC3996367. (2014)

Zimmer B, Pallocca G, Dreser N, Foerster S, Waldmann T, Westerhout J, Julien S, Krause KH, van Thriel C, Hengstler JG, Sachinidis A, Bosgra S, and Leist M

Read more

Assay Service FAQs

What techniques do you use to measure endpoints?

We use a wide range of techniques to measure endpoints, e.g. FACS, Immunostaining, ELISA, Western blot and qPCR.

Based on which cell line types can you develop assays?

Our scientific experts can develop assays based on basic cell lines, customized cell lines or iPSC-derived cell types. For this, we use our in-house differentiation protocols with cardiomyocytes, hepatocyte-like cells or neurons for your analysis. Alternatively, you can provide us with your protocol so that after the technology transfer, our experts perform the work using this protocol internally at trenzyme.

Is it possible to order both, assay development and subsequent analysis of compounds?

Yes, our assay experts are delighted to develop an assay according to your needs prior to compound analysis.

Christina Haenisch, PhD

Christina Haenisch, PhD

Head of Project & Quality Management

We would be happy to provide you with support on your stem cell research project. Let us know your questions and requests, our scientific experts will reply shortly.

Get In Contact With Our Scientific Experts

    By submitting this form, I consent to trenzyme GmbH receiving and processing my data in order to process my inquiry. My consent is voluntary and I may revoke this consent at any time without providing any reasons, e.g. by sending an email to privacy(at) with effect for the future. Further notices on data processing can be found in our privacy policy.